Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.
about
Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.Dasatinib dose management for the treatment of chronic myeloid leukemia.
P2860
Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Improved survival boosts the p ...... from a population-based study.
@en
type
label
Improved survival boosts the p ...... from a population-based study.
@en
prefLabel
Improved survival boosts the p ...... from a population-based study.
@en
P2093
P2860
P1476
Improved survival boosts the p ...... from a population-based study
@en
P2093
Joerg Hasford
Martin Tauscher
Roman Gerlach
P2860
P2888
P304
P356
10.1007/S00432-016-2155-Y
P577
2016-04-16T00:00:00Z